Clinical Use and Characteristics of the Corticosteroids

Harkins, J. D.; Carney, John M.; Tobin, Thomas

doi:10.1016/s0749-0739(17)30385-1

Cited by 38 publications

(40 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…(Cohen & Carter 1992), occurred three weeks after the last dose of corticosteroid. The longer the period of time between drug administration and disease onset, the less likely the drug was a contributing factor in the aetiology due to its reduced efficacy in the body as time passes (Harkins et al 1993). The time frame for both these two cases appears to be too long to suggest a direct causal association, especially as in both cases laminitis occurred over a week after the onset of clinical signs of systemic disease.…”

Section: Appraisal Application and Reflectionmentioning

confidence: 95%

No Evidence That Therapeutic Systemic Corticosteroid Administration is Associated With Laminitis in Adult Horses Without Underlying Endocrine or Severe Systemic Disease.

McGowan

Cooper²,

Ireland

2016

View full text Add to dashboard Cite

Clinical bottom line There is currently no conclusive evidence to support a causal association between therapeutic systemic corticosteroid administration and the development of laminitis in healthy adult horses/ponies. There is weak evidence of an association between administration of multiple doses of systemic corticosteroid and the onset of laminitis in adult horses/ponies with underlying endocrine disorders or severe systemic disease.

show abstract

Section: Appraisal Application and Reflectionmentioning

confidence: 95%

No Evidence That Therapeutic Systemic Corticosteroid Administration is Associated With Laminitis in Adult Horses Without Underlying Endocrine or Severe Systemic Disease.

McGowan

Cooper²,

Ireland

2016

View full text Add to dashboard Cite

show abstract

“…162,[167][168][169] Corticosteroids are 21-carbon molecules that contain three 6-carbon rings and a 5-carbon ring. 170 The pharmacological activity of a corticosteroid is determined by the presence of a hydroxyl group at the C-11 location. Corticosteroids are potent antiinflammatory drugs that can be used as a local intra-articular injection, or less commonly systemically, to reduce inflammation during osteoarthritis; however, the use of corticosteroids is controversial.…”

Section: -165mentioning

confidence: 99%

“…171 Corticosteroids also have several other effects including inhibition of leukocyte infiltration, suppressing leukocyte superoxide synthesis, inhibiting platelet aggregation, decreasing vascular permeability and inhibiting IL-1β and TNF-α. 170 In experimental canine studies, the use of corticosteroids has been found to delay the onset of secondary changes such as osteophytes, decrease the synthesis of inflammatory mediators and may help to protect canine chondrocytes against the effects of IL-1β.…”

mentioning

confidence: 99%

Cytokine and Growth Factor Concentrations in Canine Autologous Conditioned Serum

et al. 2016

View full text Add to dashboard Cite

(ACADEMIC)The object of this study was to compare growth factor and cytokine profiles in canine autologous conditioned serum (ACS) to canine plasma. Blood collected from 16 medium to large breed dogs was used to produce ACS (Orthokine ® vet irap 10 syringes) and citrated plasma (control). Canine-specific ELISA assays were run per manufacturers' instructions for interleukin (IL)-10, IL-4, tumor necrosis factor (TNF)-α, insulin-like growth factor (IGF)-1, fibroblast growth factor (FGF)-2, transforming growth factor (TGF)-β1, IL-1β, and interleukin-1 receptor antagonist (IL-1ra). Serum, in addition to plasma and ACS, was collected from an additional 6 dogs for TNF-α, IL-1β, and IL-1ra analysis (total of 22 dogs). Data were analyzed for differences in cytokine concentrations between ACS, plasma, and serum using the Wilcoxon signed-rank test with significance set at P<.05.There was a large variability in growth factor and cytokine concentrations between individual dogs in both plasma and ACS. There were no significant differences in IL-10, TNF-α, IGF-1, FGF-2, and TGF-β1 concentrations between ACS, plasma, or serum. ACS concentrations of IL-1β (median, range; 46.3 pg/mL, 0-828.8) and IL-4 (0.0 pg/mL, 0-244.1) were significantly increased compared to plasma (36.6 pg/mL, 0-657.1 and 0.0 pg/mL, 0-0, respectively). IL-1ra concentrations in ACS (median, range; 3458.9 pg/mL, 1,243.1-12,089.0) were significantly higher than plasma (692.3 pg/mL, 422.5-1,475.6), as was the IL-1ra:IL-1β ratio (39.9 and 7.2, respectively).iii Cytokine and Growth Factor Profiles in Canine Autologous Conditioned SerumDominique Marie Sawyere ABSTRACT (PUBLIC)Osteoarthritis (OA) is a common cause of pain and suffering in dogs and is challenging to treat effectively Current treatment for OA merely mask the signs of pain and do not promote regeneration of the damaged cartilage or alter the course of the disease. Many treatments also cause harmful side effects. Autologous conditioned serum (ACS) is a biological therapy that controls inflammation within the joint by specifically blocking the inflammatory cytokine interleukin (IL)-1β. In humans and horses ACS relieves the pain from OA and promotes cartilage regeneration. The purpose of this study was to compare levels of pro-and anti-inflammatory cytokines in canine ACS to that of normal canine plasma with the hypothesis that levels of anti-inflammatory cytokines would be higher in ACS compared to controls and that levels of pro-inflammatory cytokines would remain unchanged. Paired blood samples were collected from 22 large breed healthy dogs and processed in either irap®10 syringes (ACS) or in anti-coagulant as a control. For the last 6 dogs an additional serum sample was collected. Growth factor and cytokine levels were determined using canine-specific ELISAs. One pro-inflammatory cytokine (IL-1β) and two anti-inflammatory cytokines (IL-1ra and IL-4) were significantly higher in the ACS compared to plasma and IL-1ra levels were also higher in serum compared with plasma samples. Other levels w...

show abstract

“…Dexamethason-21-Palmitat wird unter dem Namen Lipotalon® vertrieben und hauptsächlich in der Humanmedizin zur Behandlung der rheumatoiden Arthritis eingesetzt (Lehmann et al 2002, Stein et al 1999, Hoshi et al 1985 (Hood et al 1982, Harkins et al 1993, McIlwraith 2005.…”

Section: Dexamethason-21-palmitatunclassified

Efficacy and adverse effects of joint medication in the horse – A review of the literature – Part 1: Conventional joint medication and the risks involved with joint injection in the horse

Ehrle¹,

Fürst²,

Lischer³

2013

PHK

View full text Add to dashboard Cite

Clinical Use and Characteristics of the Corticosteroids

Cited by 38 publications

References 21 publications

No Evidence That Therapeutic Systemic Corticosteroid Administration is Associated With Laminitis in Adult Horses Without Underlying Endocrine or Severe Systemic Disease.

No Evidence That Therapeutic Systemic Corticosteroid Administration is Associated With Laminitis in Adult Horses Without Underlying Endocrine or Severe Systemic Disease.

Cytokine and Growth Factor Concentrations in Canine Autologous Conditioned Serum

Efficacy and adverse effects of joint medication in the horse – A review of the literature – Part 1: Conventional joint medication and the risks involved with joint injection in the horse

Contact Info

Product

Resources

About